ANXA5 and sickle cell disease: Indeed, PS has been postulated to be a pharmacologic target in a number of non-ophthalmic diseases, and the therapeutic use of Annexin A5 to target PS has been proposed in RVO [11], cancer [17], sepsis [18,24], viral infections including COVID-19 [25,26], inflammatory bowel disease [27], osteoporosis [28], Alzheimer’s [13], vaso-occlusive crisis in sickle cell disease [29], diabetic skin wounds [16], and cardiovascular disease [14].